A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Oct 2017.